Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology announced acceptance of four abstracts from its hepatitis B clinical program for presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress, taking place virtually June 23-26, 2021. The company will host a conference call on June 25, 2021, to discuss the new data. Key presentations will focus on VIR-2218 and VIR-3434, investigational therapies targeting chronic hepatitis B. Vir aims to enhance immune responses and antiviral activity against HBV.
Vir Biotechnology will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:00 pm PT / 3:00 pm ET. The presentation will be led by CEO George Scangos, Ph.D.
A live webcast can be accessed via the Investors section of the Vir website and will be archived for 30 days post-event. The company utilizes its website for disclosing material non-public information, encouraging investors to monitor updates regularly.
Vir focuses on innovative treatments for serious infectious diseases through robust immunologic technologies.
Sotrovimab, an investigational monoclonal antibody by GSK and Vir, received FDA Emergency Use Authorization for treating mild-to-moderate COVID-19 in high-risk adults and pediatric patients. Phase 3 COMET-ICE trial showed an 85% reduction in hospitalization or death risk compared to placebo. In vitro studies confirm effectiveness against all known SARS-CoV-2 variants. Availability to patients is expected soon, with ongoing discussions for global regulatory approval. The EUA submission highlighted minor adverse events, emphasizing Sotrovimab's critical role in COVID-19 treatment.
The European Medicines Agency’s CHMP has provided a positive scientific opinion regarding the early treatment of COVID-19 with sotrovimab (previously VIR-7831). This opinion permits EU member states to consider early use of the drug prior to formal EMA marketing authorization. The opinion followed a review of the Phase 3 COMET-ICE trial, which showed an 85% reduction in hospitalization or death among treated patients. Discussions with regulators in other countries for potential authorizations are ongoing, emphasizing the urgency of effective COVID-19 treatments amid rising variants.
Vir Biotechnology and GlaxoSmithKline announced a positive scientific opinion from the EMA’s Committee for Human Medicinal Products for sotrovimab, a treatment for COVID-19, particularly in adults and adolescents at risk of severe disease. EU member states can utilize this opinion for early use decisions before formal marketing authorization. Sotrovimab is set to be available for patients in the U.S. soon. The CHMP's decision was based on an interim analysis from the Phase 3 COMET-ICE trial, demonstrating an 85% reduction in hospitalization or death, highlighting its efficacy against evolving COVID-19 variants.
Vir Biotechnology (Nasdaq: VIR) will hold its 2021 Annual General Meeting of Stockholders on May 20, 2021, at 11:30 a.m. PT, in a virtual format only. Stockholders of record as of March 22, 2021, can attend by accessing the meeting center online. Stockholders are encouraged to vote and submit their proxy ahead of the meeting. Vir Biotechnology specializes in immunology, focusing on solutions for serious infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology and GSK announced that the European Medicines Agency (EMA) has initiated a rolling review of sotrovimab, an investigational monoclonal antibody for treating COVID-19 in high-risk adults and adolescents. This review supports an upcoming Marketing Authorization Application. The EMA's assessment will consider data, including interim analyses from the Phase 3 COMET-ICE trial, where sotrovimab showed an 85% reduction in hospitalizations compared to placebo. The review process aims to expedite the authorization of sotrovimab for COVID-19 treatment.
Vir Biotechnology reported first-quarter results as of March 31, 2021, noting total revenues of $2 million, a decrease from $5.7 million in Q1 2020. Research and development expenses surged to $134.9 million, reflecting costs for COVID-19 programs, particularly VIR-7831 and VIR-2218. The net loss widened to $168.9 million, or $1.32 per share, compared to $77.2 million, or $0.71 per share, in the previous year. The company holds $733 million in cash and equivalents, bolstered by a recent equity sale to GSK. Upcoming trials and regulatory submissions highlight ongoing efforts to combat COVID-19.
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its corporate update and financial results for Q1 2021, ending March 31, 2021, on May 6, 2021. The update will be available through a press release after market close on the company's website. Vir Biotechnology focuses on treating serious infectious diseases through innovative immunological technologies, developing candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (NASDAQ: VIR) announces the dosing of its first patient in a Phase 2 clinical trial for chronic hepatitis B (HBV). The trial evaluates the combination of BRII-835 (VIR-2218), an RNA-targeted therapeutic, with BRII-179 (VBI-2601), an HBV immunotherapeutic. This marks the first evaluation of these dual mechanisms in HBV treatment, aiming for a functional cure. The study spans multiple countries, including Australia and China, and is sponsored by Brii Biosciences.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
